Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

The thrombopoietin receptor agonist romiplostim is approved for second‐line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized. This analysis of pooled data from 9 studies included patients with ITP for ≤1 year (n = 311) or >1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuter, David J., Newland, Adrian, Chong, Beng H., Rodeghiero, Francesco, Romero, Monica T., Pabinger, Ingrid, Chen, Yuqi, Wang, Kejia, Mehta, Bhakti, Eisen, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Platelets, Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593696/
https://www.ncbi.nlm.nih.gov/pubmed/30793285
http://dx.doi.org/10.1111/bjh.15803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593696/
https://www.ncbi.nlm.nih.gov/pubmed/30793285
http://dx.doi.org/10.1111/bjh.15803

Ejemplares similares